Table 2.
Key clinical characteristics of the patients related to their serological response to HPV16 antigens
| Variables | Anti-E and -L | Anti-E4-E6 and E7 | Anti L1 and -L2 | ||||||
| + | - | Sign. | + | - | Sign. | + | - | Sign. | |
| HPV DNA (%): | |||||||||
| Positive 76 | 89.5 | 10.5 | OR = 2.8 (0.8–9.9) | 71.1 | 28.9 | OR = 1.3 (0.4–3.7) | 71.1 | 28.9 | OR = 1.6 (0.6–4.6) |
| p = 0.136 | p = 0.604 | p = 0.350 | |||||||
| Negative 20 | 75.0 | 25.0 | 65.0 | 35.0 | 60.0 | 40.0 | |||
| HR-HPV (%) | |||||||||
| Positive 66 | 87.9 | 12.1 | OR = 1.4 (0.4–4.8) | 68.2 | 31.8 | OR = 0.8 (0.3–2.0) | 69.7 | 30.3 | OR = 1.1 (0.5–2.9) |
| p = 0.536 | p = 0.608 | p = 0.767 | |||||||
| Negative 30 | 83.3 | 16.7 | 73.3 | 26.7 | 66.7 | 33.3 | |||
| LR-HPV (%): | |||||||||
| Positive 10 | 100 | 0.0 | OR = NC | 90.0 | 10.0 | OR = 4.3 (0.5–30.0) | 80.0 | 20.0 | OR = 1.9 (0.4–9.7): |
| p = 0.348 | p = 0.273 | p = 0.720 | |||||||
| Negative 86 | 84.9 | 15.1 | 67.4 | 32.6 | 67.4 | 32.6 | |||
| Previous: | |||||||||
| HPV (%): | |||||||||
| Yes 19 | 94.7 | 5.3 | OR = 2.8 (0.3–23.9); | 89.5 | 10.5 | OR = 4.8 (1.1–22.8) | 73.7 | 26.3 | OR = 0.9 (0.3–3.1); |
| p = 0.445 | p = 0.046 | p = 0.961 | |||||||
| No 66 | 86.4 | 13.6 | 63.6 | 36.4 | 74.2 | 25.8 | |||
| HIV-Status (%): | |||||||||
| Negative 84 | 89.3 | 10.7 | OR = 4.2(1.1–16.5) | 71.4 | 28.6 | OR = 1.8 (0.5–6.2) | 72.6 | 27.4 | OR = 3.7 (1.1–12.9) |
| p = 0.032 | p = 0.355 | p = 0.030 | |||||||
| Positive 12 | 66.7 | 33.3 | 58.3 | 41.7 | 41.7 | 58.3 | |||
| Smokers 9 | 66.6 | 33.3 | 55.6 | 44.4 | 33.3 | 66.7 | |||
| Previous: | |||||||||
| PAP (%): | |||||||||
| Never 10 | 90.0 | 10.0 | p = 0.793 | 70.0 | 30.0 | p = 0.111 | 80.0 | 20.0 | p = 0.445 |
| Irregular 26 | 92.3 | 7.7 | 84.6 | 15.4 | 61.5 | 38.5 | |||
| Regular (1–3 yrs) 49 | 85.7 | 14.3 | 61.2 | 38.8 | 75.5 | 24.5 | |||
| Referral | |||||||||
| PAP (%): | |||||||||
| ASC-US 7 | 100 | 0.0 | p = 0.431 | 85.7 | 14.3 | p = 0.623 | 100 | 0.0 | p = 0.094 |
| LSIL 48 | 91.7 | 8.3 | 64.6 | 35.4 | 75.0 | 25.0 | p = 0.031* | ||
| HSIL 16 | 81.3 | 18.7 | 68.8 | 31.2 | 56.3 | 43.7 | |||
| Biopsy | |||||||||
| Result (%): | |||||||||
| Normal 1 | 100 | 0.0 | 0.0 | 100 | 100 | 0.0 | |||
| HPV-NCIN 9 | 100 | 0.0 | p = 0.262 | 66.7 | 33.3 | p = 0.526 | 77.8 | 22.2 | p = 0.564 |
| CIN1 11 | 90.9 | 9.1 | 54.5 | 45.5 | 63.6 | 36.4 | |||
| CIN2 14 | 92.9 | 7.1 | 71.4 | 28.6 | 85.7 | 14.3 | |||
| CIN3 15 | 93.3 | 6.7 | 73.3 | 16.7 | 73.3 | 26.7 | |||
| SCC 2 | 50.0 | 50.0 | 50.0 | 50.0 | 50.0 | 50.0 | |||
| Genital | |||||||||
| Warts (%): | |||||||||
| Yes 20 | 95.0 | 5.0 | OR = 3.3(0.4–27.7) | 80.0 | 20.0 | OR = 2.1 (0.6–7.0) | 75.0 | 25.0 | OR = 1.1 (0.4–3.7) |
| p = 0.437 | p = 0.275 | p = 0.801 | |||||||
| No 61 | 85.2 | 14.8 | 65.6 | 34.4 | 72.1 | 27.9 | |||
| Colposcopy (%): | |||||||||
| Normal 2 | 100 | 0.0 | 100 | 0.0 | 0.0 | 100 | |||
| Low-grade 27 | 96.3 | 3.74 | p = 0.177 | 63.0 | 37.0 | p = 0.668 | 85.2 | 14.8 | p = 0.015 |
| High-grade 28 | 77.8 | 22.2 | 72.2 | 27.8 | 61.1 | 28.9 | |||
NC, non-computable; 1Contraception used until past; 2Contraception in current use; *For linear trend; HPV-NCIN, HPV infection without CIN....